[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Faculty of Medicine of Tunis\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,94,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053825","office-hysteroscopy-in-postmenopausal-women-a-randomized-trial-of-cervical-preparation-strategies-100053825",false,"NCT07697781","Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies","A Four-Arm Prospective Randomized Controlled Trial Comparing Oral Misoprostol, Two Vaginal Estrogen Regimens, and No Cervical Preparation Before Office Hysteroscopy in Postmenopausal Women","Inclusion Criteria:\n\n* Women with postmenopausal status.\n* Scheduled for office hysteroscopy for the evaluation of suspected intrauterine pathology.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected hormone-dependent malignancy (e.g., breast or endometrial cancer).\n* Active genital tract infection.\n* Contraindication or known hypersensitivity to misoprostol or vaginal estrogen.\n* Refusal to undergo office hysteroscopy without anesthesia.\n* Active uterine bleeding preventing adequate hysteroscopic visualization on the day of the procedure.","FEMALE",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.\n\nThe main questions to answer are:\n\nDoes cervical preparation improve the success rate of complete office hysteroscopy in postmenopausal women? Which cervical preparation strategy provides better patient tolerance, as assessed by pain intensity during the procedure?\n\nResearchers will compare four cervical preparation protocols (14-day vaginal estrogen, 7-day vaginal estrogen, oral misoprostol, and no cervical preparation) to determine their effects on procedural success, pain, procedure duration, and perioperative complications.\n\nParticipants will be randomly assigned to one of the four cervical preparation protocols. They will undergo office hysteroscopy using a vaginoscopic (\"no touch\") approach without anesthesia. Then, they will have pain assessed using a visual analog scale (VAS) during the procedure. Finally, these informations will be collected: procedural success, procedure duration, bleeding, and perioperative complications.",[25,26,27,28,29],"Postmenopausal Women","Intrauterine Diseases","Endometrial Pathology","Postmenopausal Bleeding","Abnormal Uterine Bleeding (AUB)",[31,32,33,34,35,36,37,38,39],"Postmenopausal women","Postmenopausal bleeding","Office hysteroscopy","Cervical preparation","Vaginal estrogen","Oral misoprostol","Visual Analog Scale","Vaginoscopy","No touch approach","RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2026-01-02",{"date":48,"type":19},"2026-08-20",{"name":50,"class":51},"Faculty of Medicine of Tunis","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":65,"briefSummary":66,"conditions":67,"keywords":76,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":52},"100053679","delayed-versus-immediate-cord-clamping-in-preterm-birth-100053679","NCT07699666","Delayed Versus Immediate Cord Clamping in Preterm Birth","Early Neonatal Outcomes After Delayed Versus Immediate Cord Clamping in Preterm Birth: A Comparative Study From A Tunisian Tertiary Maternity Center","PREM-CORD","Inclusion Criteria:\n\n* Preterm neonates born at gestational age between 32 and 37 weeks\n* Live-born infants delivered in the study center\n* Singleton pregnancies\n* Parental consent obtained when applicable according to institutional ethical requirements\n\nExclusion Criteria:\n\n* Major congenital malformations or chromosomal abnormalities\n* Need for immediate advanced resuscitation at birth\n* Severe fetal distress requiring emergency obstetric intervention incompatible with protocol allocation\n* Placental conditions contraindicating delayed cord clamping (e.g., placental abruption with maternal instability, placenta previa bleeding, Placenta accreta spectrum)\n* Intra Uterin Growth Restriction with abnormal umbilical artery Doppler velocimetry","ALL","0 Days",{"count":64,"type":19},200,[22],"The goal of this study is to evaluate whether delayed cord clamping improves early neonatal outcomes compared with immediate clamping in preterm birth.\n\nPreterm infants are at higher risk of neonatal complications, and the timing of cord clamping may influence placental transfusion and neonatal adaptation after birth. Delayed cord clamping may increase blood volume, improve iron stores, and reduce some neonatal morbidities, while immediate cord clamping is still commonly practiced in many settings.\n\nIn this study, preterm newborns are assigned to either delayed or immediate cord clamping according to a predefined protocol. Early neonatal outcomes, including respiratory status, need for resuscitation, hemoglobin levels, and early morbidity and mortality, will be assessed.\n\nThe study is conducted in a tertiary maternity center in Tunisia.",[68,69,70,71,72,73,74,75],"Preterm Birth Complication","Neonatal Morbidity and Mortality","Cord Clamping","Delayed Cord Clamping","Anemia","NEC - Necrotizing Enterocolitis","Intraventricular Hemorrhage Neonatal","Respiratory Distress Neonatal",[77,78,79,80,81,82,83,84,85,86],"Delayed cord clamping","Immediate cord clamping","Preterm infants","Preterm birth","Umbilical cord clamping","Neonatal outcomes","Placental transfusion","Neonatal morbidity","Neonatal mortality","Tunisia","2026-07-08",{"date":43,"type":44},{"date":90,"type":44},"2025-10-02",{"date":92,"type":19},"2026-12-31",{"name":50,"class":51},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":52},"100632024","patent-blue-sln-in-early-ovarian-cancer-prospective-study-figo-i-ii-evaluating-patent-blue-sln-mapping-injection-into-ipuo-ligaments-in-situ-goals-assess-feasibility-and-accuracy-vs-standard-lymphadenectomy-to-minimize-surgical-morbidity-100632024","NCT07508306","Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP\u002FUO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity","Evaluation of Sentinel Lymph Node Biopsy Using Patent Blue Dye in Early-Stage Ovarian Cancer: A Prospective Observational Study","Inclusion Criteria:\n\n* Age : aged 18 years-old or older\n* Diagnosis: Suspected Ovarian cancer on MRI finding (O-RADs 4 or 5)\n* FIGO stage: Stage I or II ( Based on MRI and scanner finding)\n* Planned Procedure: Patients with planned for surgical complete stadification including pelvic and para-aortic lymphadenectomy\n* Consent: Signing of the written informed consent after full information has been provided\n\nExclusion Criteria:\n\n* Suspicious nodal involvement: Presence of suspicious lymph nodes on preoperative imaging (generally defined by a short-axis diameter ≥ 10 mm).\n* Disease extension: Radiological or intraoperative evidence of extra-pelvic metastases or peritoneal carcinomatosis.\n* Surgical history: History of lymphadenectomy, lymph node sampling, or major vascular surgery involving the aorta or the iliac vessels.\n* History of radiotherapy: Patients who have previously undergone pelvic or abdominal radiotherapy.\n* Allergies: Known allergy or adverse reaction to patent blue dyes.","18 Years",{"count":103,"type":19},30,"6 Months","OBSERVATIONAL","the standard of care in case of early ovarian cancer (stage I or II) is a complete surgery. This surgery includes : hysterectomy (remove of the uterus), bilateral salpingo-oophorectomy (remove of the adnexa), omentectomy (remove of the epiploon), bilateral pelvic lymphadenectomy (remove of pelvic lymph nodes) and para-aortic lymphadenectomy (remove of para-aortic lymph nodes). This procedure is diagnostic, curative and prognostic surgery. In fact, it allows us provider care giver to stratify the stage of the cancer, hence we give the appropriate adjuvant therapy.\n\nHowever, this surgery, especially the extended lymphadenectomy, is associated with some risks: lymphocele, vessel injury, blood loss, morbidity, long recovery period ... In order to reduce these risks, we propose a sentinel lymph node biopsy. This intervention allows us to detect first lymph node relay whether pelvic or para-aortic.\n\nIn our study, we chose the patent blue dye as a tracer. This tracer is widely used in oncologic surgery (for example in breast cancer) and approved but not in ovarian cancer yet.\n\nDuring surgery for early stage ovarian cancer, we will inject the patent blue dye on both side of the ovarian tumor. Then, we will check for first colorful lymph node, in both pelvic and para-aortic regions. We will send these dissected lymph node to pathology for analysis. Finally, we will continue the procedure as the standard of care.\n\nOur objective is to compare the results between the sentinel lymph node and the complete lymphadenectomy and to study the technique of sentinel lymph node biopsy using the blue patent dye as tracer.",[108,109],"Sentinel Lymph Node Biopsy (SLNB)","Early Stage Ovarian Tumors",[111,112,113,114],"early stage ovarian cancer","sentinel lymph node","sentinel lymph node biopsy","Patent blue dye","2026-03-31",{"date":117,"type":44},"2026-04-02",{"date":119,"type":19},"2026-04-15",{"date":121,"type":19},"2028-02-28",{"name":50,"class":51},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":61,"minAge":101,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":20,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":52},"100624449","capsular-distension-versus-corticosteroid-injection-in-adhesive-capsulitis-100624449","NCT07409779","Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis","Capsular Distension Versus Corticosteroid Injection in Patients With Adhesive Capsulitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Ability to provide informed consent\n* Shoulder pain with Visual Analog Scale (VAS) ≥ 40\u002F100\n* Limitation of external rotation \\\u003C 45° or \\\u003C 50% compared to the contralateral side\n* Clinically diagnosed adhesive capsulitis with normal shoulder radiography\n\nExclusion Criteria:\n\n* Rotator cuff tear\n* Previous shoulder surgery\n* Cervico-brachial neuralgia\n* Pregnancy or breastfeeding\n* Poorly controlled diabetes\n* Coagulation disorders or anticoagulant therapy with INR \\> 3\n* Allergy to lidocaine\n* Inflammatory rheumatic diseases\n* Severe cardiovascular or hematological diseases\n* Active infection or immunodeficiency\n* Severe psychiatric disorders\n* Recent shoulder rehabilitation (within 1 week)\n* Intra-articular corticosteroid injection or hyaluronic acid injection within the last 6 months\n* Refusal to sign informed consent","80 Years",{"count":132,"type":19},50,[22],"Adhesive capsulitis is a common and disabling shoulder condition characterized by pain and progressive limitation of range of motion. Capsular distension and intra-articular corticosteroid injection are commonly used therapeutic options, often combined with rehabilitation, but their comparative effectiveness remains debated.\n\nThe objective of this randomized controlled trial is to compare the efficacy and tolerance of ultrasound-guided capsular distension combined with rehabilitation versus intra-articular corticosteroid injection combined with rehabilitation in patients with adhesive capsulitis.\n\nOutcomes will include shoulder pain, range of motion, functional disability, patient satisfaction, and procedure-related complications, assessed at short, mid, and long-term follow-up.",[136],"Adhesive Capsulitis of the Shoulder",[138,139,140,141],"adhesive capsulitis","capsular distension","rehabilitation","corticosteroid","NOT_YET_RECRUITING","2026-03-21",{"date":145,"type":44},"2026-03-25",{"date":147,"type":19},"2026-04-01",{"date":149,"type":19},"2026-12",{"name":50,"class":51},""]